|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07H 19/173 | |
| A61K 31/7076 | |||
| C07H 19/207 | |||
| A61P 35/00 | |||
| A61P 35/02 |
| (11) | Number of the document | 3464309 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17728596.2 |
| Date of filing the European patent application | 2017-05-31 | |
| (97) | Date of publication of the European application | 2019-04-10 |
| (45) | Date of publication and mention of the grant of the patent | 2020-06-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2017/051549 |
| Date | 2017-05-31 |
| (87) | Number | WO 2017/207986 |
| Date | 2017-12-07 |
| (30) | Number | Date | Country code |
| 201609601 | 2016-06-01 | GB |
| (72) |
GRIFFITH, Hugh, GB
SERPI, Michaela, GB
SLUSARCZYK, Magdalena, GB
|
| (73) |
NuCana plc,
3 Lochside Way, Edinburgh EH12 9DT,
GB
|
| (54) | PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS |
| PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS |